Lead Product(s): Desmopressin Acetate
Therapeutic Area: Urology Product Name: Nocdurna
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: ANTARES PHARMA INC
Deal Size: $25.0 million Upfront Cash: $5.0 million
Deal Type: Licensing Agreement October 01, 2020
This license agreement for NOCDURNA expands Antares Pharma's urology portfolio, which already includes XYOSTED, the best-selling branded testosterone replacement product in the United States.